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Abstract
Background
Hip replacement is one of the most commonly performed surgical procedures worldwide;
hundreds of implant configurations provide options for femoral head size, joint surface
material and fixation method with dramatically varying costs. Robust comparative evidence
to inform the choice of implant is needed. This retrospective cohort study uses linked
national databases from England and Wales to determine the optimal type of replacement
for patients over 60 years undergoing hip replacement for osteoarthritis.
Methods and Findings
Implants included were the commonest brand from each of the four types of replacement
(cemented, cementless, hybrid and resurfacing); the reference prosthesis was the cemented
hip procedure. Patient reported outcome scores (PROMs), costs and risk of repeat (revision)
surgery were examined. Multivariable analyses included analysis of covariance to assess
improvement in PROMs (Oxford hip score, OHS, and EQ5D index) (9159 linked episodes)
and competing risks modelling of implant survival (79,775 procedures). Cost of implants and
ancillary equipment were obtained from National Health Service procurement data.
Results
EQ5D score improvements (at 6 months) were similar for all hip replacement types. In
females, revision risk was significantly higher in cementless hip prostheses (hazard ratio,
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HR = 2.22, p<0.001), when compared to the reference hip. Although improvement in OHS
was statistically higher (22.1 versus 20.5, p<0.001) for cementless implants, this small dif-
ference is unlikely to be clinically important. In males, revision risk was significantly higher
in cementless (HR = 1.95, p = 0.003) and resurfacing implants, HR = 3.46, p<0.001), with
no differences in OHS. Material costs were lowest with the reference implant (cemented,
range £1103 to £1524) and highest with cementless implants (£1928 to £4285).
Limitations include the design of the study, which is intrinsically vulnerable to omitted var-
iables, a paucity of long-term implant survival data (reflecting the duration of data collection),
the possibility of revision under-reporting, response bias within PROMs data, and issues
associated with current outcome scoring systems, which may not accurately reflect level of
improvement in some patients.
Conclusions
Cement fixation, using a polyethylene cup and a standard sized head offers good out-
comes, with the lowest risks and at the lowest costs. The most commonly used cementless
and resurfacing implants were associated with higher risk of revision and were more costly,
while perceptions of improved function and longevity were unsupported.
Introduction
Management of osteoarthritis (OA) of the hip is a significant global health burden. Hip
replacement is an established and successful treatment of end-stage OA, with excellent quality
of life improvement and cost-effectiveness [1,2]. Over 270,000 hip replacements are performed
in the United States (US) annually, and almost 90,000 within the United Kingdom (UK)
[3,4,5]. The national tariff for a hip replacement is £5280 in England. This equates to approxi-
mately £475million in annual UK healthcare costs. These costs are expected to triple over the
next five years, whilst annual volume is expected to double within ten [6].
Cemented hip replacements (which utilise a polymer known as ‘cement’ to secure the
implant in place) with a metal-on-polyethylene (MoP) articulating (‘bearing’) surface account
for one third of all hip replacements implanted in England andWales since 2003. These devices
show consistently good implant survival in long-term cohort studies and worldwide joint
replacement registries [3,6,7,8,9,10,11,12,13,14,15,16,17,18]. They utilise tried and tested tech-
nology, and are inexpensive. However, concerns of early loosening and implant failure during
the 1980s [19,20,21,22,23] drove the development of cementless implants, which rely on press-
fit stability and bone integration for fixation rather than cement [24]. Advances in engineering
also led to a proliferation of implant options available within brands; larger, more anatomical
femoral head sizes in an attempt to reduce dislocation risk, and ‘hard’ articulations, where
highly engineered metal-on-metal (MoM) or ceramic-on-ceramic (CoC) bearings are
employed in an effort to minimise long-term wear and subsequent failure [25,26,27]. Cement-
less implants now account for the majority of replacements in North America and Australia,
and their use in England andWales has recently surpassed cemented implants [3,28,29]. Resur-
facing devices, which resurface the femoral head and preserve bone (rather than excising femo-
ral head/neck and replacing with a ball and stem, as in standard hip replacement), provide near
anatomically-sized components and were introduced in the 1990s with the aim of reducing dis-
location risk, improving function and allowing an ‘easier’ revision if required [30]. These were
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designed predominantly for younger patients, but surgeons widened their indications as good
early results encouraged use in older patients. Although there is little data on implant costs in
the literature, there is a logical perception that implants with modular components (providing
numerous options), modern technologies and complex, highly engineered components are
more costly. Despite this, thorough evaluation of the evidence for different types of hip replace-
ment is absent from the literature.
Some patients with hip replacements will require a revision procedure to replace a failed or
worn implant. The National Joint Registry (NJR) was established in 2003 to provide a record of
hip replacements and any subsequent revisions performed in the pubic and private health sys-
tems in England and Wales. Patient Reported Outcomes Measures (PROMs) have been col-
lected on hip replacement patients in the public system since 2008. Linkage of these national
datasets allows the analysis of patient functional outcome following hip replacement and sub-
sequent implant failure rates for specific implants. Taking the most commonly used cemented
hip replacement as the reference implant for comparison, the objective of this study was to pro-
vide a summative evaluation of different implant types in order to determine the most cost-
effective components for hip replacement, referencing patient reported outcomes and risk of
implant revision. This study examines the eighty percent of all primary hip replacements that
are performed in patients 60 years and over [3]. Younger patients (under 60 years is arbitrarily
a reasonable threshold) may have differing demands of their prostheses, and as such have been
analysed elsewhere [31].
Methods
Design
A retrospective cohort study design assessed prospectively collected patient-level PROMs and
NJR data to compare outcomes and implant survival across different primary hip replace-
ments, with supplementary material costs for specific implant combinations obtained through
National Health Service (NHS) procurement.
Data
The single most commonly used brands of each type of hip replacement performed in England
andWales were chosen for the analysis, in order to control for brand heterogeneity within each
type (the NJR annual report provides adequate analysis of the entire breadth of replacements
available–our intention was to specifically analyse component options within brands, which
would be impossible across all brands). Individual analyses of the same data on each individual
hip replacement type have already defined component options within brand that confer the
lowest revision risk (i.e. the longest survival) [32,33,34,35]. For this current analysis we strati-
fied each hip replacement type based on these previously established component revision risks
into ‘optimal’ component sets (with significantly lower revision risk) and ‘sub-optimal’ (all
remaining component options) (Table 1).
All primary hip replacements performed using the specified implants on patients over 60
years and submitted to the NJR between 1st April 2003 and 31st December 2010 were initially
included. Subsequently, exclusion criteria were employed as follows: all procedures with an
indication other than OA; procedures with missing implant or patient data; and rarely used
implant options [32,33,34,35].
The national PROMs project uses validated measures of hip-specific (Oxford hip score
[OHS]) [36] and general health status outcomes (EuroQol [EQ-5D-3L]) [37] collected pre-
and around six months post-operatively. By linking databases at the patient level, PROMs data
can be combined with the corresponding demographic and operative details held in the NJR.
Implant Optimisation for Primary Hip Replacement
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The study population is summarised in Fig 1. The demographic, surgical and implant-related
variables available for analysis are listed in S1 Table.
For this analysis PROMs of interest were improvements between the pre- and post-opera-
tive scores (the ‘change scores’) and self-reported readmission and reoperation in the post-
operative period. Change scores, being approximately normally distributed, are analytically
preferable to post-operative scores [38]. The OHS (scored 0 lowest to 48 highest) has previ-
ously been shown to be a reliable, valid and responsive outcome measure for patients with hip
OA undergoing replacement surgery [39]. The EQ-5D index (scored 0 to 1, where 0 is no
health [i.e. dead] and 1 is perfect health) is a measure of health status used for clinical and eco-
nomic appraisal. It evaluates five different aspects of general health (mobility, self-care, usual
activities, pain/ discomfort and anxiety/depression) that are scored and combined using
Table 1. Implants studied by type of hip replacement, with descriptions of optimal and sub-optimal component configurations.
Type Brand combination Manufacturer Market share, by type (England &
Wales)
Cemented Exeter V40 stem Stryker Orthopaedics, Mahwah, New Jersey, United
States
23%
Contemporary polyethylene cup
Optimal component set:
Any Exeter stem
Flanged version of Contemporary cup
28mm or 32mm femoral head (metal or ceramic*)
Sub-optimal component set:
Small heads (<28mm)
Hooded version of Contemporary cup
Cementless Corail stem DePuy Ltd, Leeds, United Kingdom 31%
Pinnacle modular (shell and liner)
cup
Optimal component set:
Medium/large Corail stem (size 11 or greater)
Pinnacle cup / polyethylene liner (metal or ceramic head*)
Sub-optimal component set:
Small Corail stems (<size 11)
Pinnacle metal and ceramic liners*
Hybrid Exeter V40 stem Stryker Orthopaedics, Mahwah, New Jersey, United
States
33%
Trident modular (shell and liner) cup
Optimal component set:
Any Exeter stem
Solid shell Trident cup
Ceramic bearing or a XLPE liner (metal or ceramic head*)
Sub-optimal component set:
Cluster hole Trident shell
Conventional polyethylene liner
Resurfacing Birmingham Hip Resurfacing (BHR) Smith & Nephew, Memphis, Tennessee, United States 55%
Optimal component set:
Components with head size of 48mm or greater
Sub-optimal component set:
Components with head size <48mm
*grouped together as no signiﬁcant beneﬁt of options was identiﬁed, XLPE–highly cross-linked polyethylene
doi:10.1371/journal.pone.0140309.t001
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population weightings to produce a single index value for health status [37]. In this context,
readmission and reoperation are used as a crude surrogate marker for hip dislocation. Disloca-
tion occurs when the femoral component disarticulates from within the acetabular component.
This is an acute event that requires readmission and manipulation under anaesthesia to restore
normal component positions. Unfortunately this data is not captured by the NJR, but may vary
depending on head size and bearing material. Thus, to provide a summative evaluation, it is
reasonable to include these measures, despite the limitations. Within the pre-operative PROMs
questionnaire, patients are also asked about comorbidities, general health and self-reported dis-
ability. These can be used to adjust for differences in health status between patient groups.
Statistical Analysis
Implants were compared based on previously stratified revision risk within prosthesis types.
Therefore, eight groups were compared (four ‘optimal’ groups and four ‘sub-optimal’ groups)
Fig 1. Flowchart describing inclusion criteria and study populations.
doi:10.1371/journal.pone.0140309.g001
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(Fig 1). Differences in baseline characteristics across the groups were analysed using one-way
analysis of variance test (ANOVA, parametric continuous data variables), the Kruskal-Wallis
test (non-parametric continuous data variables) or the Chi-square test (categorical data
variables).
Univariable analysis was performed initially to identify variables potentially influencing
each outcome, based on statistical rejection criteria of p>0.10; these variables were then
included in the multivariable models (see supplementary material for complete statistical
methods). Due to the large population sizes and the questionable merits of statistically adjust-
ing for gender, we chose to analyse data on males and females separately.
Implant survival times for patients who had not undergone revision were censored on the
31st December 2010. Competing risks models were used to adjust for potential differences in
mortality across the implant groups, where patient death prior to either revision or censoring
was the competing risk [40]. Cumulative incidence charts were then produced for each type of
implant and by gender. Analysis of covariance (ANCOVA) was used for testing differences in
OHS and EQ5D index change scores. Multivariable logistic regression was used to analyse dif-
ferences in the risk of readmission and reoperation. Time from implantation to questionnaire
completion was included in models to evaluate whether differences in duration of follow-up
influenced findings. Pre-operative scores were included within all models, as recommended by
the designers of the OHS [39].
Results of the survival analysis were presented as hazard ratios (HRs). Statistical models for
the change scores were evaluated with the margins function in STATA in order to provide pre-
dicted values separately for each of the implant groups. P-values are provided as statistical tests
of the differences between the reference implant and the seven others. Significance was taken
as p<0.05. All values are provided with 95% confidence intervals (CIs): ratios greater than one
indicate that risk is higher when compared with the reference category. All models were fitted
using STATA 12 (StataCorp LP, Texas, USA). Further supplementary information is available
in S1 Text and S2 to S5 Tables.
Costs for specific implant combinations were provided by NHSWales (all seven hospital
Trusts) and NHS supply chain (buyers on behalf of 30 hospital Trusts within the English
NHS). Highest and lowest prices paid for implants during 2012 are provided for each of the
implant components. A mode cost was also produced at source and provided. These costs rep-
resent actual prices paid, after discounts. In addition, the NJR levy fee (£20, which is included
in the amount paid for each implant) and Value Added Tax (VAT, at 20%) were added for the
total costs. The costs presented in this study also include acetabular screws (for cementless cup
fixation) when used, the commonest cement used for each implant type, femoral cement
restrictors and all equipment required to mix and perform pressurised cementation. Although
it is acknowledged that hip replacement with cementless implants may result in slightly shorter
operative time, for the purposes of this analysis it is assumed that theatre utilisation and length
of stay was similar for all types of replacement, and that differences in specific implant costs
approximated to incremental costs.
Ethics
The National Joint Registry (England andWales) Research Committee approved this study.
Explicit patient consent is taken at the time of data collection for both the NJR and PROMs.
Further ethical approval was not required for this study. Patient records/information was
anonymized and de-identified prior to receipt of data and analysis.
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Results
There were 79,775 procedures available for implant survival analysis within the NJR dataset.
Significant baseline differences were seen in age, ASA grade, proportions of females and BMI
for the type of implant received (Table 2). Linkage of PROMs data with data stored in the NJR
dataset was possible in 9159 procedures. The demographics of patients and implants for the
linked procedures were qualitatively similar to the NJR population (Table 3). Unadjusted pre-
operative OHS and EQ5D index scores were clinically similar across the cemented, cementless
Table 2. Patient demographics for National Joint Registry population studied, by implant group.
Cemented Hybrid Cementless Resurfacing Difference
Optimal Sub-opt. Optimal Sub-opt. Optimal Sub-opt. Optimal Sub-opt.
Number (%) 19815
(24.8)
13673
(17.1)
2388 (3.0) 9768 (12.2) 9867 (12.4) 19726
(24.7)
3317 (4.2) 1221 (1.5)
Age, median
years (range)
74.8 (60 to
100)
74.8 (60 to
97)
67.6 (60 to
97)
71.7 (60 to
103)
72.2 (60 to
98)
68.7 (60 to
106)
63.8 (60 to
89)
63.3 (60 to
88)
p<0.001
Female 12788
(64.5)
9163 (67.0) 1238 (51.8) 6142 (62.9) 5303 (53.7) 11559
(58.6)
166 (5.0) 872 (71.4) p<0.001
ASA
1 2461 (12.4) 1822 (13.3) 508 (21.3) 1336 (13.7) 1219 (12.4) 2921 (14.8) 1343 (40.5) 542 (44.4) p<0.001
2 13835
(69.8)
9496 (69.5) 1637 (68.6) 6888 (70.5) 7186 (72.8) 14280
(72.4)
1833 (55.3) 644 (52.7)
3+ 3519 (17.8) 2355 (17.2) 243 (10.2) 1544 (15.8) 1462 (14.8) 2525 (12.8) 141 (4.3) 35 (2.9)
BMI, mean kg/
m2(sd, range)
28.3 (5.0, 15
to 63)
27.9 (5.0, 15
to 65)
28.4 (5.1 16
to 56)
28.1 (5.1, 15
to 61)
28.4 (5.1, 15
to 64)
28.5 (5.2, 15
to 64)
27.8 (4.3, 18
to 64)
27.3 (4.2, 18
to 40)
p = 0.015
ASA–American Society of Anesthesiologists, BMI–body mass index (data based on 34756 procedures [44%])
Statistical notes: one-way analysis of variance (ANOVA) used for parametric data, Kruskal-Wallis test for non parametric data, Chi squared test for
proportions
doi:10.1371/journal.pone.0140309.t002
Table 3. Patient demographics for National Joint Registry-PROMs linked population studied, by implant group.
Cemented Hybrid Cementless Resurfacing Difference
Optimal Sub-opt. Optimal Sub-opt. Optimal Sub-opt. Optimal Sub-opt.
Number (%) 2369 (25.9) 1133 (12.4) 300 (3.3) 1168 (12.8) 1582 (17.3) 2485 (27.2) 97 (1.1) 15 (0.2)
Age, median
years (range)
74.0 (60 to
93)
75.2 (60 to
94)
68.1 (60 to
91)
71.6 (60 to
93)
72.0 (60 to
95)
67.8 (60 to
96)
64.2 (60 to
75)
62.8 (60 to
67)
p<0.001
Female 1463 (61.8) 747 (65.9) 164 (54.7) 744 (63.7) 776 (49.1) 1425 (57.3) 1 (1.0) 13 (86.7) p<0.001
ASA
1 213 (9.0) 96 (8.5) 53 (17.7) 122 (10.5) 162 (10.2) 345 (13.9) 35 (36.1) 5 (33.3) p<0.001
2 1709 (72.1) 829 (73.2) 217 (72.3) 888 (76.0) 1201 (75.9) 1897 (76.3) 59 (60.8) 10 (66.6)
3+ 447 (18.9) 208 (18.4) 30 (10.0) 158 (13.5) 219 (13.8) 243 (9.8) 3 (3.1) 0 (0)
BMI, mean kg/m
(sd, range)
28.6 (5.0, 16
to 55)
28.1 (4.7, 15
to 46)
28.4 (4.6 17
to 44)
28.2 (4.8, 17
to 43)
28.5 (4.9, 16
to 56)
28.6 (5.2, 15
to 50)
28.0 (4.0, 20
to 38)
27.8 (2.9, 23
to 32)
p = 0.679
PROMs–patient reported outcome measures, ASA–American Society of Anesthesiologists, BMI–body mass index (data based on 5843 procedures
[64%])
Statistical notes: one-way analysis of variance (ANOVA) used for parametric data, Kruskal-Wallis test for non parametric data, Chi squared test for
proportions
doi:10.1371/journal.pone.0140309.t003
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and hybrid replacements, but higher prior to resurfacings (Table 4). Post-operative scores were
lowest in the sub-optimal cemented group and highest after any resurfacing.
Patient Reported Outcome Measures
In females OHS change was significantly higher (22.1 versus 20.5, p<0.001) in the optimal
cementless group when compared with the reference implant. No other implant combination
had a significantly better OHS improvement. There were no significant OHS improvement
benefits across the implant types in males. No implant combination displayed an EQ5D index
improvement significantly greater than the reference, in either sex (Table 5). For OHS, 40% to
42% of variation within the models could be explained by known variables; for EQ5D index
Table 4. Patient reported outcomes for populations studied, by implant group and gender.
Cemented Hybrid Cementless Resurfacing p
value
Optimal Sub-
optimal
Optimal Sub-
optimal
Optimal Sub-
optimal
Optimal Sub-
optimal
Females (n, %) 1463
(27.4)
747 (14.0) 164 (3.1) 744 (14.0) 776 (14.6) 1425
(26.7)
1 (0.0) 13 (0.2)
Oxford Hip scores
Pre-operative, mean (sd,
range)
17.4 (8.0,
0 to 44)
16.8 (8.0, 0
to 42)
19.7 (7.8, 4
to 37)
18.3 (8.0,
1 to 38)
17.3 (7.7,
1 to 43)
18.5 (8.1,
0 to 44)
13 25.9 (4.5,18
to 33)
<0.001
Post-operative, median
(range)
40 (4 to
48)
38 (2 to 48) 43 (13 to 48) 42 (5 to
48)
42 (6 to
48)
42 (2 to
48)
48 46 (21 to
48)
<0.001
EQ5D index
Pre-operative, mean (sd,
range)
0.342
(0.313,
-0.43 to 1)
0.319
(0.325, -0.48
to 1)
0.432
(0.301, -0.24
to 0.88)
0.356
(0.323,
-0.59 to 1)
0.346
(0.317,
-0.35 to 1)
0.366
(0.318,
-0.59 to 1)
0.516 0.586
(0.192, 0.09
to 0.76)
0.008
Post-operative, median
(range)
0.796
(-0.24 to 1)
0.760 (-0.24
to 1)
0.850 (-0.18
to 1)
0.814
(-0.24 to 1)
0.812
(-0.13 to 1)
0.796
(-0.32 to 1)
1 1 (0.52 to 1) <0.001
Time from op to PROMs
complete, mean days (sd,
range)
208.8
(29.0, 183
to 358)
209.5 (29.2,
183 to 358)
209.5 (30.6,
184 to 360)
209.4
(28.5, 183
to 364)
207.2
(25.8, 185
to 357)
208.3
(28.4, 183
to 360)
193 258.8 (46.8,
192 to 316)
0.323
Males (n, %) 906 (23.7) 386 (10.1) 136 (3.6) 424 (11.1) 806 (21.1) 1060
(27.8)
96 (2.5) 2 (0.1)
Oxford Hip scores
Pre-operative, mean (sd,
range)
19.8 (7.9,
0 to 44)
19.1 (8.1, 2
to 48)
22.1 (7.9, 4
to 41)
20.4 (8.5,
2 to 42)
19.9 (8.0,
2 to 42)
20.4 (8.3,
3 to 44)
25.7 (8.2, 4
to 43)
21.5 (0.7,21
to 22)
0.001
Post-operative, median
(range)
43 (7 to
48)
41 (12 to 48) 44 (14 to 48) 43 (11 to
48)
43 (2 to
48)
44 (1 to
48)
45 (13 to
48)
48 <0.001
EQ5D index
Pre-operative, mean (sd,
range)
0.425
(0.300,
-0.32 to 1)
0.439
(0.288, -0.48
to 0.88)
0.439
(0.288, -0.07
to 0.80)
0.422
(0.302,
-0.35 to 1)
0.418
(0.301,
-0.35 to 1)
0.425
(0.311,
-0.35 to 1)
0.551
(0.253,
-0.18 to 81)
0.516 0.016
Post-operative, median
(range)
0.814
(-0.18 to 1)
0.814 (-0.18
to 1)
0.883 (0.88
to 1)
1 (-0.24 to
1)
0.850
(-0.18 to 1)
0.883
(-0.59 to 1)
1 (-0.02 to
1)
1 <0.001
Time from op to PROMs
complete, mean days (sd,
range)
208.2
(28.5, 183
to 363)
207.6 (27.2,
183 to 355)
208.5 (27.1,
183 to 336)
205.0
(22.3, 184
to 355)
207.9
(28.7, 183
to 363)
207.2
(27.5, 183
to 362)
272.4
(44.3, 184
to 336)
195.5 (3.5,
193 to 198)
0.192
SD–standard deviation, PROMs–patient reported outcome measures
Statistical notes: one-way analysis of variance (ANOVA) used for parametric data, Kruskal-Wallis test for non parametric data, Chi squared test for
proportions
doi:10.1371/journal.pone.0140309.t004
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this was 61% to 63% (S4 Table). There were no significant differences in readmission or further
surgery (Table 6).
Implant Revision Risk
When compared to the reference hip in females, the following had significantly higher revision
risks: sub-optimal cemented (HR = 1.85, p<0.001), sub-optimal hybrid (HR = 1.68, p = 0.012),
optimal cementless (HR = 2.22, p<0.001), sub-optimal cementless (HR = 3.60, p<0.001), and
sub-optimal resurfacing (HR = 8.74, p<0.001). Optimal hybrid and optimal resurfacing had
similar implant survival, but confidence intervals were wide for resurfacing (Table 7).
Table 5. Patient reported outcome scores following hip replacement in patients aged 60 years and over (simple andmultivariable analyses).
Simple Multivariable
Value 95% CI P value Value 95% CI P value
Females (n = 5333)
Change in OHS
Optimal cemented (n = 1463) 20.2 19.7 to 20.7 Reference 20.5 20.1 to 21.0 Reference
Sub-optimal cemented (n = 747) 19.2 18.4 to 19.9 0.029 19.7 19.0 to 20.5 0.075
Optimal hybrid (n = 164) 20.4 18.9 to 21.9 0.773 21.7 20.0 to 23.4 0.207
Sub-optimal hybrid (n = 744) 20.7 20.0 to 21.4 0.227 20.9 20.1 to 21.6 0.463
Optimal cementless (n = 776) 21.9 21.2 to 22.6 <0.001 22.1 21.3 to 22.8 <0.001
Sub-optimal cementless (n = 1425) 20.7 20.2 to 21.2 0.169 21.0 20.4 to 21.5 0.270
Change in EQ5D index
Optimal cemented (n = 1463) 0.421 0.402 to 0.439 Reference 0.426 0.414 to 0.439 Reference
Sub-optimal cemented (n = 747) 0.429 0.403 to 0.454 0.619 0.418 0.398 to 0.439 0.502
Optimal hybrid (n = 164) 0.373 0.320 to 0.427 0.103 0.452 0.404 to 0.499 0.312
Sub-optimal hybrid (n = 744) 0.433 0.408 to 0.459 0.421 0.436 0.416 to 0.457 0.430
Optimal cementless (n = 776) 0.446 0.421 to 0.471 0.100 0.447 0.427 to 0.467 0.086
Sub-optimal cementless (n = 1425) 0.417 0.398 to 0.435 0.765 0.420 0.404 to 0.435 0.182
Males (n = 3826)
Change in OHS
Optimal cemented (n = 906) 20.1 19.5 to 20.7 Reference 20.3 19.7 to 20.9 Reference
Sub-optimal cemented (n = 386) 20.4 19.5 to 21.4 0.553 19.9 18.9 to 20.9 0.521
Optimal hybrid (n = 136) 20.0 18.3 to 21.6 0.882 18.9 17.2 to 20.6 0.140
Sub-optimal hybrid (n = 424) 20.5 19.6 to 21.4 0.488 20.6 19.7 to 21.5 0.603
Optimal cementless (n = 806) 20.7 20.0 to 21.3 0.222 20.6 19.9 to 21.3 0.521
Sub-optimal cementless (n = 1060) 20.2 19.6 to 20.8 0.820 19.8 19.1 to 20.5 0.295
Optimal resurfacing (n = 96) 17.1 15.2 to 19.0 0.004 19.1 17.2 to 21.1 0.282
Change in EQ5D index
Optimal cemented (n = 906) 0.379 0.357 to 0.401 Reference 0.390 0.374 to 0.407 Reference
Sub-optimal cemented (n = 386) 0.417 0.384 to 0.450 0.060 0.391 0.364 to 0.418 0.988
Optimal hybrid (n = 136) 0.377 0.322 to 0.432 0.941 0.364 0.316 to 0.411 0.302
Sub-optimal hybrid (n = 424) 0.419 0.387 to 0.450 0.044 0.415 0.389 to 0.441 0.121
Optimal cementless (n = 806) 0.395 0.371 to 0.418 0.345 0.401 0.381 to 0.421 0.428
Sub-optimal cementless (n = 1060) 0.390 0.370 to 0.410 0.482 0.358 0.340 to 0.377 0.011
Optimal resurfacing (n = 96) 0.340 0.273 to 0.406 0.270 0.398 0.343 to 0.453 0.790
OHS–Oxford Hip Score, CI–conﬁdence interval
Note: No predicted values are available for resurfacings in females (14 PROMs available only) and others resurfacing in males (2 PROMs only)
doi:10.1371/journal.pone.0140309.t005
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For males, all implants except hybrids had significantly higher revision risk: sub-optimal
cemented (HR = 2.09, p = 0.001), optimal cementless (HR = 1.95, p = 0.003), sub-optimal
cementless (HR = 2.53, p<0.001), optimal resurfacing (HR = 3.46, p<0.001) and sub-optimal
resurfacing (HR = 6.21, p<0.001) (Table 7).
Material Costs
The reference (cemented) replacement in this analysis was the cheapest (most commonly paid
total price £1138). Resurfacing implants ranged in total cost from £2018 to £2991. A cementless
36mm CoC implant cost the NHS between £2500 and £4285 (Table 8).
Table 6. Risk of readmission and reoperation following hip replacement in patients aged 60 years and over (simple andmultivariable analyses).
Simple Multivariable
Number (%) OR 95% CI P value OR 95% CI P value
Females (n = 5333)
Readmission
Optimal cemented (n = 1463) 92 (6.3) 1 1
Sub-opt. cemented (n = 747) 67 (8.9) 1.47 1.06 to 2.04 0.022 1.67 1.11 to 2.51 0.013
Optimal hybrid (n = 164) 8 (4.9) 0.76 0.36 to 1.60 0.477 1.76 0.23 to 2.50 0.651
Sub-optimal hybrid (n = 744) 47 (6.3) 1.00 0.70 to 1.44 0.979 1.24 0.77 to 2.00 0.379
Optimal cementless (n = 776) 56 (7.2) 1.16 0.82 to 1.64 0.401 1.25 0.79 to 1.98 0.340
Sub-opt cementless (n = 1425) 82 (5.8) 0.91 0.67 to 1.24 0.547 1.18 0.78 to 1.78 0.423
Reoperation
Optimal cemented (n = 1463) 29 (2.0) 1 1
Sub-opt. cemented (n = 747) 20 (2.7) 1.36 0.76 to 2.42 0.296 1.22 0.67 to 2.22 0.522
Optimal hybrid (n = 164) 3 (1.8) 0.92 0.28 to 3.06 0.894 0.99 0.29 to 3.31 0.982
Sub-optimal hybrid (n = 744) 15 (2.0) 1.02 0.54 to 1.91 0.957 0.95 0.50 to 1.82 0.879
Optimal cementless (n = 776) 6 (0.8) 0.39 0.16 to 0.93 0.034 0.46 0.16 to 1.35 0.156
Sub-opt cementless (n = 1425) 27 (1.9) 0.96 0.56 to 1.62 0.865 0.83 0.47 to 1.46 0.519
Males (n = 3826)
Readmission
Optimal cemented (n = 906) 88 (9.7) 1 1
Sub-opt. cemented (n = 386) 32 (8.3) 0.84 0.55 to 1.28 0.420 0.97 0.57 to 1.63 0.894
Optimal hybrid (n = 136) 14 (4.5) 1.07 0.59 to 1.93 0.832 0.74 0.29 to 1.93 0.542
Optimal cementless (n = 806) 69 (8.6) 0.87 0.63 to 1.21 0.410 0.82 0.53 to 1.27 0.381
Sub-opt cementless (n = 1060) 68 (6.4) 0.64 0.46 to 0.87 0.007 0.77 0.50 to 1.19 0.238
Optimal resurfacing (n = 96) 4 (4.2) 0.40 0.15 to 1.13 0.083 0.60 0.18 to 2.03 0.411
Reoperation
Optimal cemented (n = 906) 21 (2.3) 1 1
Sub-opt. cemented (n = 386) 6 (1.6) 0.67 0.27 to 1.66 0.383 0.85 0.31 to 2.34 0.749
Optimal hybrid (n = 136) 5 (3.7) 1.61 0.59 to 4.34 0.348 1.34 0.37 to 4.83 0.658
Sub-optimal hybrid (n = 424) 6 (1.4) 0.60 0.24 to 1.51 0.281 0.55 0.18 to 1.68 0.297
Optimal cementless (n = 806) 17 (2.1) 0.91 0.48 to 1.73 0.770 0.47 0.18 to 1.21 0.116
Sub-opt cementless (n = 1060) 18 (1.7) 0.73 0.39 to 1.37 0.328 0.72 0.33 to 1.56 0.409
Optimal resurfacing (n = 96) 1 (1.0) 0.44 0.06 to 3.33 0.430 1 -
OR–odds ratio, CI–conﬁdence interval
Note: No predicted values are available for resurfacings in females (14 PROMs available only) and others resurfacing in males (2 PROMs only)
doi:10.1371/journal.pone.0140309.t006
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Discussion
The reference implant (fully cemented, standard head size and conventional polyethylene cup)
offered the lowest risk of implant failure at the lowest cost in patients over 60 years. No func-
tional benefit of any implant was found in males relative to the reference implant; some differ-
ences for females were statistically significant but of unclear clinical importance. Readmission
and reoperation rates were similar across all groups, suggesting there are no large variations in
dislocation risk across implants. Notably higher costs and poorer implant survival was found
when resurfacing and cementless implants were used. The findings of this summative evalua-
tion of a range of hip replacements are contrary to current trends in surgery and may be useful
for healthcare providers, surgeons and those commissioning hip replacement services.
As with all database analyses, the study design is observational and thus vulnerable to omit-
ted variables. Implant choices in this cohort result from the interplay of patient, surgical and
provider factors, and are not assigned randomly. Potentially important variables that were
unavailable, such as radiological data, race, socioeconomic status, patient experiences, levels of
perioperative pain and preoperative expectations, are known to influence outcome [41,42]; a
large proportion of variation within the models in this study therefore remains unexplained.
The numbers within comparison groups were adequate in order to identify meaningful dif-
ferences in PROMs, despite limiting to specific brands (to reduce the confounding effect of
implant heterogeneity) [38]. Additionally, raw data from the NJR annual report suggests no
other brands afford better implant survival than the commonest brands as used here [3].
Whilst the NJR only describes mid-term implant survival, there is currently no evidence
to support the assertion that polyethylene-wear associated revision may occur in greater num-
bers beyond ten years, as other national registries established many decades ago show good
Table 7. Risk of revision following hip replacement in patients aged 60 years and over (simple andmultivariable analyses).
Simple Multivariable
HR 95% CI P value HR 95% CI P value
Females (n = 47231)
Optimal cemented (n = 12788) 1 1
Sub-optimal cemented (n = 9163) 1.77 1.28 to 2.44 0.001 1.85 1.31 to 2.61 <0.001
Optimal hybrid (n = 1238) 1.30 0.60 to 2.85 0.507 1.26 0.56 to 2.81 0.578
Sub-optimal hybrid (n = 6142) 1.73 1.19 to 2.52 0.004 1.68 1.12 to 2.52 0.012
Optimal cementless (n = 5303) 2.15 1.47 to 3.14 <0.001 2.22 1.48 to 3.34 <0.001
Sub-optimal cementless (n = 11559) 3.62 2.70 to 4.85 <0.001 3.60 2.63 to 4.94 <0.001
Optimal resurfacing (n = 166) 1.98 0.49 to 8.07 0.339 2.31 0.57 to 9.41 0.244
Sub-optimal resurfacing (n = 872) 7.66 5.21 to 11.3 <0.001 8.74 5.81 to 13.2 <0.001
Males (n = 32544)
Optimal cemented (n = 7027) 1 1
Sub-optimal cemented (n = 4510) 2.03 1.36 to 3.04 0.001 2.09 1.37 to 3.18 0.001
Optimal hybrid (n = 1150) 0.94 0.40 to 2.21 0.882 0.68 0.26 to 1.76 0.425
Sub-optimal hybrid (n = 3626) 1.47 0.92 to 2.37 0.108 1.28 0.78 to 2.11 0.327
Optimal cementless (n = 4564) 2.08 1.36 to 3.16 0.001 1.95 1.25 to 3.05 0.003
Sub-optimal cementless (n = 8167) 2.79 1.95 to 3.98 <0.001 2.53 1.74 to 3.68 <0.001
Optimal resurfacing (n = 3151) 3.30 2.23 to 4.88 <0.001 3.46 2.28 to 5.26 <0.001
Sub-optimal resurfacing (n = 349) 6.13 3.37 to 11.2 <0.001 6.21 3.36 to 11.5 <0.001
HR–hazard ratio, CI–conﬁdence interval
doi:10.1371/journal.pone.0140309.t007
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Table 8. Cost of specific hip implant combinations (NHS costs 2011/12).
Implant description Stem Femoral head Cup Ancillary items Cost,
mode /
range (£)
Total
cost*
(£)Description Cost
(£)
Description Cost
(£)
Description Cost (£) Description Cost (£)
CEMENTED Stryker Exeter V40 Contemporary
Most
commonly
used
‘optimal’
component
set
Flanged
cup /
28mm
metal
head
44/size 1 397.90
to
547.40
Stainless
steel
(Orthinox)
V40
standard
offset
28mm
145.00
to
257.60
Flanged cup 138.40
to
227.50
Heraeus Palacos R
+Gentamycin antibiotic
cement (4 mixes required)
26.75 /mix 928.41
(898.88
to
1250.08)
1138.09
Alternative
‘optimal’
Flanged
cup /
32mm
ceramic
head
44/size 1 397.90
to
547.40
Ceramic
(Alumina)
V40
standard
offset
32mm
415.00
to
588.00
Flanged cup 138.40
to
227.50
DePuy Hardinge restrictor 22.00 1343.41
(951.30
to
1580.48)
1636.09
Most
commonly
used ‘sub-
optimal’
Hooded
cup/
26mm
head
44/ size 1 397.90
to
547.40
Stainless
steel
(Orthinox)
standard
offset
26mm
138.40
to
227.50
Hooded cup 138.40
to
227.50
Biomet Optivac vacuum
mixing and delivery
system (2 required)
44.29 /kit 928.41
(898.88
to
1250.08)
1138.09
HYBRID Stryker Exeter V40 Trident
Most
commonly
used
‘optimal’
component
set
Solid
shell/
36mm
CoC
44/ size 1 397.90
to
547.40
Ceramic
(Alumina)
V40
standard
offset
36mm
415.00
to
588.00
Ceramic
36mm liner
plus PSL
solid back
shell
415.00
to
717.50
plus
432.40
to
646.10
Heraeus Palacos R
+Gentamycin antibiotic
cement (2 mixes required)
DePuy Hardinge
restrictorBiomet Optivac
vacuum mixing and
delivery system (1
required)
26.75
/mix22.0044.29
1780.09
(1780.09
to
2618.79)
2160.11
Alternative
‘optimal’
Solid
shell/
32mm
MoXLP
44/ size 1 397.90
to
547.40
Cobalt-
chrome
(Vitallium)
V40
standard
offset
32mm
145.00
to
271.60
X3 XLPE
32mm 10
degree liner
plus PSL
solid back
shell
345.14
to
506.80
plus
432.40
to
646.10
1465.00
(1440.23
to
2091.69)
1782.00
Most
commonly
used ‘sub-
optimal’
Multi-
hole
shell/
28mm
MoP
44/ size 1 397.90
to
547.40
Cobalt-
chrome
(Vitallium)
V40
standard
offset
28mm
145.00
to
271.60
Conventional
Polyethylene
28mm liner
plus PSL
5-hole
230.09
to
375.20
plus
432.40
to
646.10
As above, plus 2 Stryker
acetabular screws
40.00 to 51.10 1405.18
(1405.18
to
2051.19)
1710.22
RESURFACING Smith & Nephew Birmingham Hip Resurfacing
Optimal Head
size
48mm
- - BHR head 540.00
to
865.52
BHR cup 1050.00
to
1534.81
Stryker Antibiotic Simplex
cement (1 mix required)
27.72 1943.71
(1662.01
to
2472.34)
2356.45
Sub-
optimal
Head
size
<48mm
- - BHR head 540.00
to
865.52
BHR cup 1050.00
to
1534.81
CEMENTLESS DePuy Corail Pinnacle
(Continued)
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long-term survival of cemented implants with polyethylene bearings (cemented polyethylene
cup 90% survival at 16 years, compared with 85% for cementless, Swedish Annual Report
2011) [11]. A systematic review of world wide registry and cohort study data failed to show a
benefit of other bearings when compared with MoP [6]. Furthermore, dislocation risk has been
shown to be higher with CoC [43] and there are concerns surrounding metal wear debris reac-
tions in patients with MoM implants, which has prompted a dramatic reduction in their use
over the last five years [3,44].
This analysis covers an entire nation of surgeons and surgical units providing hip replace-
ment, and therefore provides strong external validity. However, NJR data validity has been
questioned; data loss and under-reporting of revision numbers remains a concern (although
this should affect comparison groups equally). PROMs data are currently recorded only once
post-operatively, at around six months following surgery, which may be too early to determine
success of a joint replacement. Nevertheless, the greatest improvement in OHS occurs in the
first three months, with no improvements seen beyond 12 months; results from this current
study are therefore a reliable indication of longer-term outcome [45,46]. There may also be
selection bias within the PROMs data; questionnaire response rates may vary across different
ages, socioeconomic groups or race. The point at which a patient undergoes a hip procedure
may also be different (reflecting the need to adjust for pre-operative scores), depending on age,
expectations and occupation. Patients undergoing resurfacing tend to have higher pre-opera-
tive scores. This may in turn limit their ability to improve within the constraints of the current
scoring systems, due to a ceiling effect of both the OHS and EQ5D index.
Pennington et al recently published a cost effectiveness paper using NJR, PROMs and
implant cost data to compare types of hip replacement [47]. Hybrid implants were found to
Table 8. (Continued)
Implant description Stem Femoral head Cup Ancillary items Cost,
mode /
range (£)
Total
cost*
(£)Description Cost
(£)
Description Cost
(£)
Description Cost (£) Description Cost (£)
Most
commonly
used
‘optimal’
component
set
28mm
MoP
Size 11 KS 642.85
to 1118
Metal
standard
offset
28mm
130.53
to
227.00
Marathon
28mm PE
neutral lip
liner plus
cluster-hole
Duoﬁx
252.43
to
439.00
plus
510.03
to
887.00
1 DePuy acetabular screw
included
54.05 1586.94
(1586.94
to
2722.10)
1928.33
Commonly
used ‘sub-
optimal’
36mm
MoM
Size 11 KS 642.85
to 1118
Ultamet
standard
offset
36mm
249.55
to
434.00
Metal liner
plus Sector
cluster-hole
Duoﬁx
249.55
to
434.00
plus
510.03
to
887.00
1790.78
(1703.08
to
2924.10)
2172.94
Commonly
used ‘sub-
optimal’
36mm
CoC
Size 11 KS 642.85
to 1118
Ceramic
36mm
standard
offset
431.25
to
750.00
Ceramic liner
plus Sector
cluster-hole
Duoﬁx
428.38
to
745.00
plus
510.03
to
887.00
2209.95
(2063.61
to
3551.10)
2675.94
CoC–ceramic-on-ceramic, MoXLP–metal-on-highly cross-linked polyethylene, MoP–metal-on polyethylene, MoM–metal-on-metal, PE–polyethylene.
Figures based on actual implant costs paid to manufacturers by NHS Wales (seven Trusts) and NHS Supply chain (30 Trusts in England). *Total cost is
calculated using the mode cost plus NJR levy costs (£20) and Value Added Tax (20%). Note–very large Exeter stems (offset 44 sizes 4 and 5, and all 50
offset stems) increase cost by £614.27 (this represents less than 5% of all Exeter stems used) [32]
doi:10.1371/journal.pone.0140309.t008
Implant Optimisation for Primary Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0140309 November 12, 2015 13 / 18
have the most cost-effective profile. Corroborating the findings presented in this current study,
the authors found that cementless implants offered no benefit whilst being more costly. How-
ever, all brands within each hip replacement type were analysed collectively (using only MoP
bearings), with no adjustment for the heterogeneity of implants. This limits the implications of
their findings as pooling brands and configurations (when comparing procedures) may mask
important differences between brand, configuration and procedure. However, Pulikottil-Jacob
et al took this a step further by examining different types of hip replacement fixation and bear-
ing, and found that available evidence does not support recommending a particular device on
cost effectiveness grounds alone, although the authors did not examine PROMs or complica-
tion data [48].
Although hybrid implants have good implant survival in this current study, it must be
stressed these results rely on rigid press-fit of the acetabular component into the bony socket
without the need for supplementary screws to aid fixation. The use of multi-hole shells to allow
supplementary screw fixation (as apposed to ‘solid’ shells, without holes) have a 37% higher
risk of revision [34]. Whilst a cemented procedure will have reproducible results, adequate
cementless cup fixation may be more difficult to achieve.
The fully cementless implant analysed here has a 1.9 to 3.6 times higher revision risk than
the standard cemented implant. Although there was a higher OHS improvement (1.6 points)
in females, this is below the clinical important threshold of 3 to 5 points suggested by the OHS
designers [39,49]. Proponents of fully cementless procedures argue that the costs may actually
be lower than those of cemented implants, as cementation requires greater operative time [50].
Although we chose to analyse the commonest cementless implant, we acknowledge that others
may have lower costs. We have assumed that implant specific costs approximate to the incre-
mental costs of different implants. There remains no good evidence of improved theatre effi-
ciency for cementless implants in the literature; savings of 15 to 20 minute per case have been
suggested [50,51,52], but equating this to monetary savings is only credible when extra replace-
ments are actually performed within an operating schedule. Additionally, our analysis is likely
to understate the true incremental costs of implants: subsequent revision surgery (which occurs
more commonly with cementless and resurfacing procedures) would increase the overall costs
of these types relative to cemented implants. One study found that annual hip replacement
costs in the US (where cementless implants are used almost exclusively) could be reduced by
$2billion if there was a joint registry comparable to the Swedish registry (enabling reductions
in revision rates) [53]. The use of cement on the femoral side has many advantages that out-
weigh the disadvantage of a slightly longer operative time [28], and the available literature sug-
gests that cemented fixation of acetabular components is more reliable than cementless beyond
the first postoperative decade [14].
This study demonstrates no benefit of a resurfacing procedure in patients over 60 years
across any of the domains studied in this analysis. Given the high failure rates, the risks of local
and systemic complications, and the long-term concerns surrounding these implants, includ-
ing a medical device warning and mandatory annual follow-up, there appears to be no routine
place for a resurfacing procedure in patients over 60 years [44,54]. Even in the ideal resurfacing
patient (a young male), Heintzbergen et al showed that absolute differences in cost-utility were
small when a BHR was compared to conventional hip replacement [55]. A dramatic fall in the
use of resurfacings, with use predominantly in young males during 2011 suggests surgeons
practising in England and Wales are responding to the evidence [3].
Long-term observational studies of mortality after hip replacement suggest a higher risk of
death when cement is used, but these fail to account for the confounding effect of true patient
differences and provide no logical reason for the increased death rate many years after cemen-
tation [56,57]. However, an analysis of over 400,000 hip replacements performed in England
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andWales between 2003 and 2011, using a combination of NJR and hospital episodes data
(allowing for extensive patient and provider variable adjustment) found the use of hip replace-
ment type to have no impact on mortality at 90 days following surgery [58], implying that
cement pressurisation at the time of surgery does not influence surgery-associated mortality.
In the past decade hip surgeons have been guilty of using implants with limited long-term
evidence at great expense to the NHS and other healthcare providers (as a result of costs
incurred initially and at revision surgery), and with significant adverse impact on patient out-
comes [59]. Fordham et al stated that the most cost-effective implants are those with the best
survival rates (and hence the fewest revisions), with the best patient outcomes and the least
cost [1]. Within this multi-outcome study of national data, a cemented stem with a cemented
polyethylene cup and a standard sized head offered similar outcomes to other implants, but
with lower revision risk and at the lowest costs. This category of implant should be the gold
standard for hip replacement, and used for comparisons with new implants within future
robust, randomised clinical trials. Uptake of new implants should depend upon evidence of
reduced revisions, patient morbidity and healthcare resource use.
The proliferation of hip replacement options has meant that any analysis aiming to deter-
mine ‘optimal’ hip replacement is inherently complex. However, the intention of this study was
to provide a summative evaluation of a range of hip replacements for the patient over 60 years
with hip OA. This type of evaluation is crucial to inform commissioning decisions by helping
to answer the question 'what is the most cost-effective hip replacement?’ We believe the find-
ings of this paper will appeal to commissioners, surgeons, healthcare management and the
broader medical community striving to delivery high quality and cost effective healthcare.
Supporting Information
S1 Table. Summary of the demographic and surgical variables available for analysis.
(PDF)
S2 Table. Variables included in the competing risks survival model.
(PDF)
S3 Table. Competing risks survival modelling of hip type using different variable sets.
(PDF)
S4 Table. Variables included in the change score analysis of covariance models.
(PDF)
S5 Table. Variables included in the complications multivariable logistic regression models.
(PDF)
S1 Text. Supplementary methodology.
(PDF)
Acknowledgments
We thank the patients and staff of all the hospitals in England and Wales who have contributed
data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement
Partnership (HQIP), the NJR steering committee and the staff at the NJR centre for facilitating
this work.
We also thank Andrew Smallwood (NHSWales) and Philip Lewis (NHS Supply chain) for
their provision of, and help with, implant costs data.
Implant Optimisation for Primary Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0140309 November 12, 2015 15 / 18
STROBE Statement
This study was carried out in accordance with the STROBE checklist.
Author Contributions
Conceived and designed the experiments: SJ MR PG. Performed the experiments: SJ. Analyzed
the data: SJ. Contributed reagents/materials/analysis tools: PB JM. Wrote the paper: SJ JMMR
PB DD PG.
References
1. Fordham R, Skinner J, Wang X, Nolan J (2012) The economic benefit of hip replacement: a 5-year fol-
low-up of costs and outcomes in the Exeter Primary Outcomes Study. BMJ Open 2.
2. Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR (2013) Predicting the cost-
effectiveness of total hip and knee replacement: a health economic analysis. Bone Joint J 95-B: 115–
121. doi: 10.1302/0301-620X.95B1.29835 PMID: 23307684
3. England-and-Wales-National-Joint-Registry (2012) National Joint Registry for England andWales 9th
Annual Report.
4. No-authors-listed (2012) Scottish Arthroplasty Project Biennial Report 2012.
5. Kurtz S, Ong K, Lau E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee
arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89: 780–785. PMID:
17403800
6. Sedrakyan A, Normand SL, Dabic S, Jacobs S, Graves S, Marinac-Dabic D (2011) Comparative
assessment of implantable hip devices with different bearing surfaces: systematic appraisal of evi-
dence. BMJ 343: d7434. doi: 10.1136/bmj.d7434 PMID: 22127517
7. Australian-National-Joint-Registry (2010) Australian Orthopaedic Association, National Joint Replace-
ment Register.
8. New-Zealand-National-Joint-Registry (2008) Annual Report 2008, 8 year report. New Zealand National
Joint Registry.
9. Norwegian-Arthroplasty-Registry (2008) Annual Report 2008. Norwegian Arthroplasty Register.
10. Finnish-National-Arthoplasty-Registry (2006) Annual Report 2006. Finnish National Arthroplasty
Register.
11. Swedish-Hip-Registry (2011) Annual report 2011. Swedish Hip Registry.
12. Busch V, Klarenbeek R, Slooff T, Schreurs BW, Gardeniers J (2010) Cemented hip designs are a rea-
sonable option in young patients. Clin Orthop Relat Res 468: 3214–3220. doi: 10.1007/s11999-010-
1355-z PMID: 20405346
13. Schmitz MW, Busch VJ, Gardeniers JW, Hendriks JC, Veth RP, Schreurs BW (2013) Long-term results
of cemented total hip arthroplasty in patients younger than 30 years and the outcome of subsequent
revisions. BMCMusculoskelet Disord 14: 37. doi: 10.1186/1471-2474-14-37 PMID: 23339294
14. Toossi N, Adeli B, Timperley AJ, Haddad FS, Maltenfort M, Parvizi J (2013) Acetabular components in
total hip arthroplasty: is there evidence that cementless fixation is better? J Bone Joint Surg Am 95:
168–174. doi: 10.2106/JBJS.K.01652 PMID: 23324965
15. Pakvis D, van Hellemondt G, de Visser E, JacobsW, Spruit M (2011) Is there evidence for a superior
method of socket fixation in hip arthroplasty? A systematic review. Int Orthop 35: 1109–1118. doi: 10.
1007/s00264-011-1234-6 PMID: 21404024
16. Berry DJ, HarmsenWS, Cabanela ME, Morrey BF (2002) Twenty-five-year survivorship of two thou-
sand consecutive primary Charnley total hip replacements: factors affecting survivorship of acetabular
and femoral components. J Bone Joint Surg Am 84-A: 171–177. PMID: 11861721
17. Callaghan JJ, Bracha P, Liu SS, Piyaworakhun S, Goetz DD, Johnston RC (2009) Survivorship of a
Charnley total hip arthroplasty. A concise follow-up, at a minimum of thirty-five years, of previous
reports. J Bone Joint Surg Am 91: 2617–2621. doi: 10.2106/JBJS.H.01201 PMID: 19884436
18. Wroblewski BM, Siney PD, Fleming PA (2007) Charnley low-friction arthroplasty: survival patterns to
38 years. J Bone Joint Surg Br 89: 1015–1018. PMID: 17785737
19. Chandler HP, Reineck FT, Wixson RL, McCarthy JC (1981) Total hip replacement in patients younger
than thirty years old. A five-year follow-up study. J Bone Joint Surg Am 63: 1426–1434. PMID:
7320033
Implant Optimisation for Primary Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0140309 November 12, 2015 16 / 18
20. Dorr LD, Takei GK, Conaty JP (1983) Total hip arthroplasties in patients less than forty-five years old. J
Bone Joint Surg Am 65: 474–479. PMID: 6833321
21. Sharp DJ, Porter KM (1985) The Charnley total hip arthroplasty in patients under age 40. Clin Orthop
Relat Res: 51–56.
22. Ranawat CS, Atkinson RE, Salvati EA, Wilson PD Jr. (1984) Conventional total hip arthroplasty for
degenerative joint disease in patients between the ages of forty and sixty years. J Bone Joint Surg Am
66: 745–752. PMID: 6725322
23. Collis DK (1984) Cemented total hip replacement in patients who are less than fifty years old. J Bone
Joint Surg Am 66: 353–359. PMID: 6699050
24. Lord GA, Hardy JR, Kummer FJ (1979) An uncemented total hip replacement: experimental study and
review of 300 madreporique arthroplasties. Clin Orthop Relat Res: 2–16.
25. Sedel L, Kerboull L, Christel P, Meunier A, Witvoet J (1990) Alumina-on-alumina hip replacement.
Results and survivorship in young patients. J Bone Joint Surg Br 72: 658–663. PMID: 2380223
26. Delaunay CP, Bonnomet F, Clavert P, Laffargue P, Migaud H (2008) THA using metal-on-metal articu-
lation in active patients younger than 50 years. Clin Orthop Relat Res 466: 340–346. doi: 10.1007/
s11999-007-0045-y PMID: 18196415
27. Cuckler JM, Moore KD, Lombardi AV Jr., McPherson E, Emerson R (2004) Large versus small femoral
heads in metal-on-metal total hip arthroplasty. J Arthroplasty 19: 41–44.
28. Murray DW (2011) Cemented femoral fixation: the North Atlantic divide. Orthopedics 34: e462–463.
doi: 10.3928/01477447-20110714-25 PMID: 21902131
29. Australian-National-Joint-Registry (2012) Australian National Joint Replacement Registry Annual
Report 2012.
30. Spencer RF (2011) Evolution in hip resurfacing design and contemporary experience with an uncemen-
ted device. J Bone Joint Surg Am 93 Suppl 2: 84–88. doi: 10.2106/JBJS.J.01716 PMID: 21543695
31. Jameson SS MJ, Baker PN, Gregg PJ, Porter M, Deehan DJ, Reed MR (2013) HAVE CEMENTLESS
AND RESURFACING COMPONENTS IMPROVEDHIP REPLACEMENT FOR PATIENTS UNDER 60
YEARS? AN ANALYSIS OF PATIENT REPORTEDOUTCOMEMEASURES, IMPLANT SURVIVAL
AND COSTS. Submitted to Acta Orthop.
32. Jameson SS, Baker PN, Mason J, Gregg PJ, Brewster N, Deehan DJ, et al. (2012) The design of the
acetabular component and size of the femoral head influence the risk of revision following 34 721 sin-
gle-brand cemented hip replacements: A retrospective cohort study of medium-term data from a
National Joint Registry. J Bone Joint Surg Br 94: 1611–1617. doi: 10.1302/0301-620X.94B12.30040
PMID: 23188900
33. Jameson SS BP, Mason JM, Rymaszewska M, Gregg PJ, Deehan DJ, Reed MR (2013) Independent
predictors of failure up to 7.5 years after 35 386 single-brand cementless total hip replacements. Bone
and Joint Jounal In press.
34. Jameson SS, Mason JM, Baker PN, Jettoo P, Deehan DJ, Reed MR (2013) Factors Influencing Revi-
sion Risk Following 15 740 Single-Brand Hybrid Hip Arthroplasties: A Cohort Study From a National
Joint Registry. J Arthroplasty.
35. Jameson SS, Baker PN, Mason J, Porter ML, Deehan DJ, Reed MR (2012) Independent predictors of
revision following metal-on-metal hip resurfacing: a retrospective cohort study using National Joint Reg-
istry data. J Bone Joint Surg Br 94: 746–754. doi: 10.1302/0301-620X.94B6.29239 PMID: 22628587
36. Dawson J, Fitzpatrick R, Carr A, Murray D (1996) Questionnaire on the perceptions of patients about
total hip replacement. J Bone Joint Surg Br 78: 185–190. PMID: 8666621
37. No-authors-listed (2009) EuroQol (EQ5D Score).
38. Browne J JL, Lewsey J, et al. (2007) Patient reported outcomemeasures (PROMs) in elective surgery:
report to the Department of Health, 2007.
39. Murray DW, Fitzpatrick R, Rogers K, Pandit H, Beard DJ, Carr AJ, et al. (2007) The use of the Oxford
hip and knee scores. J Bone Joint Surg Br 89: 1010–1014. PMID: 17785736
40. Fine J, Gray R. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal
of the American Statistical Association 94: 496–509.
41. Hamilton DF, Lane JV, Gaston P, Patton JT, Macdonald D, Simpson AH, et al. (2013) What determines
patient satisfaction with surgery? A prospective cohort study of 4709 patients following total joint
replacement. BMJ Open 3.
42. Clement ND, Muzammil A, Macdonald D, Howie CR, Biant LC (2011) Socioeconomic status affects the
early outcome of total hip replacement. J Bone Joint Surg Br 93: 464–469. doi: 10.1302/0301-620X.
93B4.25717 PMID: 21464483
Implant Optimisation for Primary Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0140309 November 12, 2015 17 / 18
43. Sexton SA, Walter WL, Jackson MP, De Steiger R, Stanford T (2009) Ceramic-on-ceramic bearing sur-
face and risk of revision due to dislocation after primary total hip replacement. J Bone Joint Surg Br 91:
1448–1453. doi: 10.1302/0301-620X.91B11.22100 PMID: 19880888
44. Medicines-and-Healthcare-products-Regulatory-Agency (2011) Medical Device Alert: All metal-on-
metal (MoM) hip replacements (MDA/2012/008).
45. Judge A, Arden NK, Batra RN, Thomas G, Beard D, Javaid MK, et al. (2013) The association of patient
characteristics and surgical variables on symptoms of pain and function over 5 years following primary
hip-replacement surgery: a prospective cohort study. BMJ Open 3.
46. Andrew JG, Palan J, Kurup HV, Gibson P, Murray DW, Beard DJ (2008) Obesity in total hip replace-
ment. J Bone Joint Surg Br 90: 424–429. doi: 10.1302/0301-620X.90B4.20522 PMID: 18378913
47. Pennington M, Grieve R, Sekhon JS, Gregg P, Black N, van der Meulen JH (2013) Cemented, cement-
less, and hybrid prostheses for total hip replacement: cost effectiveness analysis. BMJ 346: f1026. doi:
10.1136/bmj.f1026 PMID: 23447338
48. Pulikottil-Jacob R, Connock M, Kandala NB, Mistry H, Grove A, Freeman K, et al. (2015) Cost effective-
ness of total hip arthroplasty in osteoarthritis: comparison of devices with differing bearing surfaces and
modes of fixation. Bone Joint J 97-B: 449–457. doi: 10.1302/0301-620X.97B4.34242 PMID: 25820881
49. Beard DJ, Harris K, Dawson J, Doll H, Murray DW, Carr AJ, et al. (2015) Meaningful changes for the
Oxford hip and knee scores after joint replacement surgery. J Clin Epidemiol 68: 73–79. doi: 10.1016/j.
jclinepi.2014.08.009 PMID: 25441700
50. Kallala R. PA, Morris S., Haddad F. S. (2013) The cost analysis of cemented versus cementless total
hip replacement operations on the NHS. Bone Joint J 95-B: 874–876. doi: 10.1302/0301-620X.95B7.
26931 PMID: 23814235
51. Barrack RL, Castro F, Guinn S (1996) Cost of implanting a cemented versus cementless femoral stem.
J Arthroplasty 11: 373–376. PMID: 8792242
52. Yates P, Serjeant S, Rushforth G, Middleton R (2006) The relative cost of cemented and uncemented
total hip arthroplasties. J Arthroplasty 21: 102–105. PMID: 16446193
53. Larsson S, Lawyer P, Garellick G, Lindahl B, LundstromM (2012) Use of 13 disease registries in 5
countries demonstrates the potential to use outcome data to improve health care's value. Health Aff
(Millwood) 31: 220–227.
54. Haddad FS, Thakrar RR, Hart AJ, Skinner JA, Nargol AV, Nolan JF, et al. (2011) Metal-on-metal bear-
ings: the evidence so far. J Bone Joint Surg Br 93: 572–579. doi: 10.1302/0301-620X.93B4.26429
PMID: 21511920
55. Heintzbergen S, Kulin NA, Ijzerman MJ, Steuten LM, Werle J, Khong H, et al. (2013) Cost-utility of
metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients
with osteoarthritis. Value Health 16: 942–952. doi: 10.1016/j.jval.2013.06.021 PMID: 24041344
56. McMinn DJ, Snell KI, Daniel J, Treacy RB, Pynsent PB, Riley RD (2012) Mortality and implant revision
rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study. BMJ 344: e3319.
doi: 10.1136/bmj.e3319 PMID: 22700782
57. Kendal AR, Prieto-Alhambra D, Arden NK, Carr A, Judge A (2013) Mortality rates at 10 years after
metal-on-metal hip resurfacing compared with total hip replacement in England: retrospective cohort
analysis of hospital episode statistics. BMJ 347: f6549. doi: 10.1136/bmj.f6549 PMID: 24284336
58. Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, et al. (2013) 90-day mortality
after 409,096 total hip replacements for osteoarthritis, from the National Joint Registry for England and
Wales: a retrospective analysis. Lancet 382: 1097–1104. doi: 10.1016/S0140-6736(13)61749-3 PMID:
24075049
59. Cohen D (2011) Out of joint: the story of the ASR. BMJ 342: d2905. doi: 10.1136/bmj.d2905 PMID:
21572134
Implant Optimisation for Primary Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0140309 November 12, 2015 18 / 18
